NCT00036738 - Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 13, 2001

Primary Completion Date

July 31, 2014

Study Completion Date

May 31, 2018

Conditions

Adult Acute Lymphoblastic Leukemia in RemissionAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Blastic PhaseChildhood Acute Lymphoblastic Leukemia in RemissionChildhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Chronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase of DiseaseRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Disease

Interventions

DRUG

Cyclosporine

Given IV or PO

DRUG

Dasatinib

Given PO

DRUG

Fludarabine Phosphate

Given IV

DRUG

Imatinib Mesylate

Given PO

DRUG

Mycophenolate Mofetil

Given PO

DRUG

Nilotinib

Given PO

PROCEDURE

Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Undergo nonmyeloablative allogeneic PBSC transplantation

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo allogeneic PBSC transplantation

BIOLOGICAL

Therapeutic Allogeneic Lymphocytes

Given IV

RADIATION

Total-Body Irradiation

Undergo TBI

Trial Locations (3)

80218

Presbyterian - Saint Lukes Medical Center - Health One, Denver

98101

VA Puget Sound Health Care System, Seattle

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER